Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases

Applied Health Economics and Health Policy

Volumn 12, Issue 5, 2014, Pages 547-557

  Seal, Brian ^a   Sullivan, Sean D ^b   Ramsey, Scott D ^c   Asche, Carl V ^d   Shermock, Ken ^e   Sarma, Syam ^f   Zagadailov, Erin A ^g   Farrelly, Eileen ^g   Eaddy, Michael ^g  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Xcenda ^*  (United States)

^g XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID DERIVATIVE; IRIDIUM; KETOCONAZOLE; PALLADIUM; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CARE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ICD-9; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTPATIENT; OUTPATIENT CARE; PROSTATE CANCER; RACE; TRANSURETHRAL RESECTION; AGED; AMBULATORY CARE; BONE NEOPLASMS; COMPARATIVE STUDY; ECONOMICS; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PROSTATIC NEOPLASMS; RESOURCE ALLOCATION; SECONDARY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; BONE NEOPLASMS; COHORT STUDIES; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RESOURCE ALLOCATION;

EID: 84919871441     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0101-1     Document Type: Article

References (26)

1. American Cancer Society. Cancer Facts & Figures 2012. http://www.cancer.org/Research/ CancerFactsFigures/index. Accessed 3 Aug 2012.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10–29.
3. Howlader N, Noone AM, Krapcho M (eds) et al. SEER Cancer Statistics Review, 1975-2009. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/. Based on November 2011 SEER data submission, posted to the SEER website, 2012.
4. ™. Prostate cancer, v3.2012. NCCN. http://www.nccn.org. Accessed 3 Aug 2012.
5. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. Prostate. AJCC Cancer Staging Manual 7th ed. New York, NY: Springer; 2010.
6. Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol. 2011;29(Suppl 6):S1–8.
7. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56:594–605.
8. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.
9. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.
12. Ryan CJ, de Bono JS, Molina A, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase 3 study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: American Society of Clinical Oncology (ASCO); May 31–June 4, 2012; Chicago, IL.
13. Red Book Online. Micromedex 2.0, Truven Health Analytics, Inc. Accessed 11 Dec 2012.
14. Scher HI, Halabi S, Tannock I, et al. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.
15. Zelefsky MJ, Eastham JA, Sartor OA, et al. Cancer of the prostate. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer Principles & Practice of Oncology, vol. 2, 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins and Wolters Kluwer. 2008. p 1392–1452
16. Scher HI, Morris MJ, Basch E, et al. Endpoints and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29:3695–704.
17. Konski A, James J, Hartsell W, et al. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol. 2009;32:423–8.
18. Janjan N, Lutz ST, Bedwinek JM, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med. 2009;12:417–26.
19. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;4:1358–65.
20. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.
21. de Bono JS, Fizazi K, Saad F, et al. Phase 3 trial (AFFIRM) of enzalutamide (MDV3100), an androgen receptor signaling inhibitor: primary, secondary, and quality-of-life endpoint results. Presentation presented at: American Society of Clinical Oncology (ASCO); May 31–June 4, 2012; Chicago, IL.
22. Milenkovic M, Russo CA, Elixhauser A. Hospital stays for prostate cancer, 2004. Healthcare Cost and Utilization Project. Statistical Brief #30. May 2007.
23. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CPRC) patients with bone metastases (ALSYMPCA). Presented at: American Society of Clinical Oncology (ASCO); May 29–June 2, 2009; Orlando, FL.
24. Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden or prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:162–7.
25. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2001;93:388–95.
26. Jones J. African-Americans and prostate cancer: why the discrepancies? J Natl Cancer Inst. 2001;93:342–4.